| Name | Title | Contact Details |
|---|
The Integrated Health and Social Services University Network for West-Central Montreal (CIUSSS West-Central Montreal) is one of the largest health and social services network in the Montreal area, regrouping over 20 establishments in the west end of Montreal and serving a population of nearly 345,000. We are making the difference, one person at a time. CIUSSS West-Central Montreal`s services and programs span the continuum of healthcare, from hospital to community integrated services to residential care. Our 9,000 employees, including 900 doctors, are guided by values of compassion, integrity and commitment to the quality of care. We are proud of our official bilingual status and the culturally rich identities of our sites. On top of clinical activities, research and teaching play an integral part in the CIUSSS West-Central Montreal network.
KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.
Tanita Corporation of America, Inc. is a Arlington Heights, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sturgis Hospital is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Sturgis, MI. To find more information about Sturgis Hospital, please visit www.sturgishospital.com
Corwin Medical Care is a Plainfield, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.